Search Results - john+sedivy

3 Results

Sort By:

Small-Molecule Inhibitors of the L-1 Endonuclease Domain

Overview Chronic inflammation is a hallmark of a number of age-related diseases, as well as of aging itself. Nuclear element-1 (L1) plays a key role in this inflammatory process. We have developed the first inhibitors of the L-1 endonuclease (EN) domain and the first of any retrotransposon-encoded EN. Our technology sheds light on the regulators that...

Published: 7/25/2023 | Inventor(s): John Sedivy, Gerwald Jogl, Alexandra D'Ordine

Keywords(s):

Category(s): Therapeutics

Compositions and Methods for Selectively Detecting and Purifying Line-1 cDNA Synthesized in Vivo

Overview Many age-related diseases, as well as aging itself, are closely associated with chronic low-level inflammation. We have invented a method for treating, preventing, and/or reversing age-associated inflammation by administering a reverse transcriptase inhibitor (RTI) to patients who have a level of retrotransposable element (RTE)-derived Line-1...

Published: 6/7/2023 | Inventor(s): John Sedivy, Alexandra D'Ordine, Anna Petrashen

Keywords(s):

Category(s): Research Tools

L1 Inhibitor to Prevent Age-Associated Inflammation and Disease

Overview One hallmark of aging is the accumulation of senescent cells that contribute to sterile inflammation, which underlies many age-associated diseases such as osteoarthritis, cancer, and neurodegeneration. Nuclear element-1 (L1), which represents approximately 17% of the human genome, plays a key role in this process. We are identifying candidates...

Published: 1/21/2023 | Inventor(s): John Sedivy, Gerwald Jogl, Alexandra D'Ordine

Keywords(s):

Category(s): Therapeutics